Crossmark

Psychiatrist-led hepatitis C (HCV) treatment at an opioid agonist treatment clinic in Stockholm– a model to enhance the HCV continuum of care

Published Online: 2025-03-27

Authors

Klasa, Per-Erik

Sandell, Mikael

Aleman, Soo

Kåberg, Martin https://orcid.org/0000-0001-6643-3245
Funding

Funding for this research was provided by:

Karolinska Institute
License Information

Text and Data Mining valid from 2025-03-27

Version of Record valid from 2025-03-27
More Information

Article History

Received: 3 September 2023

Accepted: 17 March 2025

First Online: 27 March 2025

Declarations

:

: The study was performed in accordance with the Helsinki Declaration and was approved by the Regional Ethical Review Board in Stockholm (Dnr: 2019 − 002016). All HCV treated participants at the Maria OAT clinic were informed about the study and provided written informed consent.

: Not applicable.

: PEK has received honoraria for lectures from Gilead and Indivior; SA has received payment or honoraria for lectures and educational events from Gilead, AbbVie, Merck Sharp & Dohme, Biogen, not related to this work; MK has received honoraria for lectures/consultancy from AbbVie, Gilead, MSD, Mundipharma, DnE Pharma, Nordic Drugs and has received research grants from Gilead and Nordic Drugs. No conflicts of interest exist for the remaining author.

Document is current